Navigation Links
Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today that the Company intends to initiate a Phase 1b clinical trial to demonstrate the efficacy and safety of the improved formulation of its transdermal insulin product, TPM-02/Insulin, containing long-acting insulin. The trial is expected to commence in the second quarter of 2007.

TPM-02/Insulin gel is being developed as a novel "needle-free" way of administering insulin to patients with diabetes. Following the successful completion of a Phase 1a study utilizing short-acting insulin, this trial will assess an optimized formulation of long-acting insulin. Recent advancements in Phosphagenics' patented TPM-02 delivery system have enabled the formulation of long-acting insulin; which is significantly less expensive than short- acting insulin, provides appropriate levels of insulin in humans and is commercially attractive.

"In August of 2006, our Phase 1a study demonstrated that a single application of TPM-02/Insulin gel rapidly delivered insulin across the skin and into the bloodstream without any adverse reactions," said Dr. Esra Ogru, Executive Vice President at Phosphagenics. "Additionally, it significantly lowered blood glucose, insulin and c-peptide levels."

"The Phase 1b study is intended to provide additional supporting data for an Investigational New Drug application to the U.S. Food and Drug Administration," continued Dr. Ogru. "The trial will be conducted by CMAX at the Royal Adelaide Hospital, South Australia, will include up to 45 healthy volunteers and is expected to lead directly into the start of a large multi- site Phase 2 trial that is likely to include up to several hundred patients."

"This is an important step for the development and commercialization of TPM-02/Insulin," said Harry Rosen, President and CEO of Phosphagenics. "This technology has the potential to p rovide diabetics with a non-invasive and effective treatment, and we look forward to its continued development."

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics' stock on the 'over-the-counter' market.

For more information, please visit Phosphagenics' web site at http://www.phosphagenics.com

CONTACT: Company - Dr. Esra Ogru, Executive Vice President Research &Development, Phosphagenics Limited, +61-3-9605-5900, or Mr. Harry Rosen,President and CEO, Phosphagenics Limited, +61-3-9605-5900; or U.S. Investorand Media - Brian Ritchie or Evan Smith, both of FD, +1-212-850-5600

Web site: http://www.phosphagenics.com/

Ticker Symbol: (NASDAQ-OTCBB:PPGNY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... FOREST KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... and health topics, but she has not found any of them to be very ... weekly actions to slowly and easily make changes in their health. It prompted her ...
Breaking Medicine News(10 mins):